Prostate cancer treatment targeting genetic mutations could extend lives

Written by Caitlin Killen, Future Science group

A Phase III trial has demonstrated the benefit of treating prostate cancer based on its genetic profile. The results from the PROfound trial were announced at the 2019 European Society for Medical Oncology Congress (27 September–1 October, Barcelona, Spain) during the Presidential Symposium. The trial results demonstrate that prostate cancer patients may be successfully treated with therapies targeting the genetic mutations that their tumors acquire. The patients included in the trial suffered from metastatic prostate cancer that had progressed after previous treatment. The trial preselected patients whose cells had mutations in genes implicated in cellular repair processes – specifically BRACA1,...

To view the full article, please register now for access

It's completely free